{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T05:36:58Z","timestamp":1769924218192,"version":"3.49.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00277-018-3546-8","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T05:28:39Z","timestamp":1542950919000},"page":"1-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Navigating the treatment landscape in multiple myeloma: which combinations to use and when?"],"prefix":"10.1007","volume":"98","author":[{"given":"Hartmut","family":"Goldschmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"3546_CR1","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C, ESMO Guidelines Committee (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv52\u2013iv61. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx096","journal-title":"Ann Oncol"},{"issue":"5","key":"3546_CR2","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516\u20132520. \n                    https:\/\/doi.org\/10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"issue":"5","key":"3546_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122\u20131128. \n                    https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"issue":"10","key":"3546_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327\u20131337. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30578-8","journal-title":"Lancet Oncol"},{"key":"3546_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40487-015-0009-4","volume":"3","author":"JT Larsen","year":"2015","unstructured":"Larsen JT, Kumar S (2015) Evolving paradigms in the management of multiple myeloma: novel agents and targeted therapies. Rare Cancers Ther 3:47\u201368. \n                    https:\/\/doi.org\/10.1007\/s40487-015-0009-4","journal-title":"Rare Cancers Ther"},{"issue":"3","key":"3546_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/leu.2013.350","volume":"28","author":"EM Ocio","year":"2014","unstructured":"Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF (2014) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28(3):525\u2013542. \n                    https:\/\/doi.org\/10.1038\/leu.2013.350","journal-title":"Leukemia"},{"issue":"2","key":"3546_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, Aspire Investigators (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142\u2013152. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1411321","journal-title":"N Engl J Med"},{"issue":"1","key":"3546_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, Endeavor Investigators (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27\u201338. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00464-7","journal-title":"Lancet Oncol"},{"key":"3546_CR9","doi-asserted-by":"publisher","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P, Eloquent Investigators (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621\u2013631. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1505654","DOI":"10.1056\/NEJMoa1505654"},{"key":"3546_CR10","doi-asserted-by":"publisher","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, Tourmaline-MM Study Group (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1516282","DOI":"10.1056\/NEJMoa1516282"},{"issue":"16","key":"3546_CR11","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","volume":"122","author":"A Larocca","year":"2013","unstructured":"Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omede P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A (2013) Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study. Blood 122(16):2799\u20132806. \n                    https:\/\/doi.org\/10.1182\/blood-2013-03-488676","journal-title":"Blood"},{"issue":"11","key":"3546_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14(11):1055\u20131066. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70380-2","journal-title":"Lancet Oncol"},{"issue":"4","key":"3546_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00277-014-2238-2","volume":"94","author":"IJ Lau","year":"2015","unstructured":"Lau IJ, Smith D, Aitchison R, Blesing N, Roberts P, Peniket A, Yong K, Rabin N, Ramasamy K (2015) Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and\/or refractory to bortezomib and lenalidomide. Ann Hematol 94(4):643\u2013649. \n                    https:\/\/doi.org\/10.1007\/s00277-014-2238-2","journal-title":"Ann Hematol"},{"issue":"11","key":"3546_CR14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Blade J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15(11):1195\u20131206. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(14)70440-1","journal-title":"Lancet Oncol"},{"issue":"8","key":"3546_CR15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, CASTOR Investigators (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754\u2013766. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1606038","journal-title":"N Engl J Med"},{"issue":"14","key":"3546_CR16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, POLLUX Investigators (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319\u20131331. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"N Engl J Med"},{"issue":"8","key":"3546_CR17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1634\/theoncologist.2014-0042","volume":"19","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Sonneveld P, Davies F, Blade J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A (2014) European perspective on multiple myeloma treatment strategies in 2014. Oncologist 19(8):829\u2013844. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2014-0042","journal-title":"Oncologist"},{"issue":"5","key":"3546_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1586\/ehm.12.49","volume":"5","author":"A Nooka","year":"2012","unstructured":"Nooka A, Lonial S (2012) Sequential or combination therapy for multiple myeloma. Expert Rev Hematol 5(5):533\u2013545. \n                    https:\/\/doi.org\/10.1586\/ehm.12.49","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"3546_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","volume":"120","author":"JJ Keats","year":"2012","unstructured":"Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120(5):1067\u20131076. \n                    https:\/\/doi.org\/10.1182\/blood-2012-01-405985","journal-title":"Blood"},{"issue":"17","key":"3546_CR20","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","volume":"65","author":"M Altun","year":"2005","unstructured":"Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM (2005) Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 65(17):7896\u20137901. \n                    https:\/\/doi.org\/10.1158\/0008-5472.can-05-0506","journal-title":"Cancer Res"},{"issue":"4","key":"3546_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","volume":"30","author":"KC Anderson","year":"2012","unstructured":"Anderson KC (2012) The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30(4):445\u2013452. \n                    https:\/\/doi.org\/10.1200\/jco.2011.37.8919","journal-title":"J Clin Oncol"},{"issue":"1","key":"3546_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","volume":"270","author":"NW Donk van de","year":"2016","unstructured":"van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, Lokhorst HM, Parren PW (2016) Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 270(1):95\u2013112. \n                    https:\/\/doi.org\/10.1111\/imr.12389","journal-title":"Immunol Rev"},{"issue":"4","key":"3546_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bmt.2015.307","volume":"51","author":"RF Cornell","year":"2016","unstructured":"Cornell RF, Kassim AA (2016) Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant 51(4):479\u2013491. \n                    https:\/\/doi.org\/10.1038\/bmt.2015.307","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3546_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, Wasch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A, European Myeloma Network (2014) European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99(2):232\u2013242. \n                    https:\/\/doi.org\/10.3324\/haematol.2013.099358","journal-title":"Haematologica"},{"issue":"6","key":"3546_CR25","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/annonc\/mdn018","volume":"19","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V, Caravita T, Morabito F, Magarotto V, Ruggeri M, Avonto I, Musto P, Cascavilla N, Bruno B, Boccadoro M (2008) Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 19(6):1160\u20131165. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdn018","journal-title":"Ann Oncol"},{"key":"3546_CR26","doi-asserted-by":"publisher","unstructured":"Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA, NCRI Haematological Oncology Study Group (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118(5):1231\u20131238. \n                    https:\/\/doi.org\/10.1182\/blood-2011-02-338665","DOI":"10.1182\/blood-2011-02-338665"},{"issue":"9758","key":"3546_CR27","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M, GIMEMA Italian Myeloma Network (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376(9758):2075\u20132085. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(10)61424-9","journal-title":"Lancet"},{"issue":"30","key":"3546_CR28","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, Michallet M, Maisonneuve H, Benboubker L, Maloisel F, Petillon MO, Webb I, Mathiot C, Moreau P (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28(30):4621\u20134629. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.9158","journal-title":"J Clin Oncol"},{"issue":"6","key":"3546_CR29","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","volume":"115","author":"HM Lokhorst","year":"2010","unstructured":"Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P, Dutch-Belgian Hemato-Oncology Group (2010) A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115(6):1113\u20131120. \n                    https:\/\/doi.org\/10.1182\/blood-2009-05-222539","journal-title":"Blood"},{"issue":"22","key":"3546_CR30","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","volume":"118","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pegourie B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traulle C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118(22):5752\u20135758. \n                    https:\/\/doi.org\/10.1182\/blood-2011-05-355081","journal-title":"Blood"},{"key":"3546_CR31","doi-asserted-by":"publisher","unstructured":"Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J, Granell M, Besalduch J, Palomera L, Gonzalez Y, Etxebeste MA, Diaz-Mediavilla J, Hernandez MT, de Arriba F, Gutierrez NC, Martin-Ramos ML, Cibeira MT, Mateos MV, Martinez J, Alegre A, Lahuerta JJ, San Miguel J, Blade J, Programa para el Estudio y la Terapeutica de las Hemopatias Malignas\/Grupo Espanol de Mieloma g (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study. Blood 120(8):1589\u20131596. \n                    https:\/\/doi.org\/10.1182\/blood-2012-02-408922","DOI":"10.1182\/blood-2012-02-408922"},{"issue":"24","key":"3546_CR32","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 30(24):2946\u20132955. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.39.6820","journal-title":"J Clin Oncol"},{"issue":"8","key":"3546_CR33","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2015.80","volume":"29","author":"EK Mai","year":"2015","unstructured":"Mai EK, Bertsch U, Durig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29(8):1721\u20131729. \n                    https:\/\/doi.org\/10.1038\/leu.2015.80","journal-title":"Leukemia"},{"issue":"21","key":"3546_CR34","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","volume":"127","author":"P Moreau","year":"2016","unstructured":"Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M (2016) VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 127(21):2569\u20132574. \n                    https:\/\/doi.org\/10.1182\/blood-2016-01-693580","journal-title":"Blood"},{"issue":"33","key":"3546_CR35","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","volume":"33","author":"R Niesvizky","year":"2015","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J (2015) Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol 33(33):3921\u20133929. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.58.7618","journal-title":"J Clin Oncol"},{"key":"3546_CR36","doi-asserted-by":"publisher","unstructured":"Mateos M-V, San Miguel JF (2012) Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 3(2):117\u2013124. \n                    https:\/\/doi.org\/10.1177\/2040620711432020","DOI":"10.1177\/2040620711432020"},{"issue":"9","key":"3546_CR37","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","volume":"120","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R (2012) A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120(9):1801\u20131809. \n                    https:\/\/doi.org\/10.1182\/blood-2012-04-422683","journal-title":"Blood"},{"issue":"6","key":"3546_CR38","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"N Korde","year":"2015","unstructured":"Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O (2015) Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 1(6):746\u2013754. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2015.2010","journal-title":"JAMA Oncol"},{"key":"3546_CR39","doi-asserted-by":"crossref","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Belhadj K, Facon T, Garderet L, Escoffre M, Pegourie B, Benboubker L, Caillot D, Fohrer C, Moreau P, Leleu X, Avet-Loiseau H, Attal M (2016) Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, KRd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the Intergroupe Francophone Du My\u00e9Lome (IFM) KRd phase II study. ASH Annual Meeting Abstracts A1142","DOI":"10.1182\/blood.V128.22.1142.1142"},{"key":"3546_CR40","doi-asserted-by":"crossref","unstructured":"Moreau P, Hulin C, Caillot D, Marit G, Perrot A, Garderet L, Facon T, Benboubker L, Karlin L, Tiab M, Arnulf B, Fermand JP, Leleu X, Touzeau C, Roussel M, Planche L, Minivielle S, Bene M, Avet-Loiseau H, Dejoie T, Attal M (2016) Ixazomib-lenalidomide-dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance in patients with newly diagnosed multiple myeloma (NDMM): a phase 2 study from the Intergroupe Francophone Du My\u00e9Lome (IFM). ASH Annual Meeting Abstracts A674","DOI":"10.1182\/blood.V128.22.674.674"},{"key":"3546_CR41","unstructured":"ECOG-ACRIN Cancer Research Group (2016) Bortezomib or carfilzomib with lenalidomide and dexamethasone in treating patients with newly diagnosed multiple myeloma. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01863550?term=NCT01863550&rank=1\n                    \n                  . Accessed June 2016"},{"key":"3546_CR42","unstructured":"University of Leeds (2016) Use of thalidomide, lenalidomide, carfilzomib, bortezomib and vorinostat in the initial treatment of newly diagnosed multiple myeloma patients (Myeloma XI). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01554852\n                    \n                  . Accessed August 2016"},{"key":"3546_CR43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V126.23.189.189","volume":"126","author":"C Pawlyn","year":"2015","unstructured":"Pawlyn C, Davies FE, Cairns DA, Collett C, Chalmers A, Striha A, Jones JR, Garg M, Allotey D, Karunanithi K, Milligan D, Kaiser MF, Jenner MW, Cook G, Russell NH, Drayson MT, Owen RG, Gregory WM, Jackson GH, Morgan GJ (2015) Quadruplet vs sequential triplet induction therapy approaches to maximise response for newly diagnosed, transplant eligible, myeloma patients. Blood 126:189","journal-title":"Blood"},{"key":"3546_CR44","unstructured":"Pawlyn C, Davies F, Cairns DA, Striha A, Waterhouse A, Collett C, Jones J, Kishore B, Garg M, Williams C, Karunanithi K, Lindsay J, Jenner M, Cook G, Kaiser M, Drayson M, Owen RG, Russell N, Gregory W, Morgan G, Jackson GH (2017) Quadruplet vs sequential triplet induction therapy for myeloma patients results of the myeloma XI study. Abstract S407. Haematologica 102(s2):1\u2013882"},{"key":"3546_CR45","unstructured":"Center UoHM (2016) A phase III trial on the effect of elotuzumab in VRD induction \/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma (GMMG-HD6). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02495922?term=NCT02495922&rank=1\n                    \n                  . Accessed June 2016"},{"issue":"4","key":"3546_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/joim.12590","volume":"281","author":"O Landgren","year":"2017","unstructured":"Landgren O, Iskander K (2017) Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med 281(4):365\u2013382. \n                    https:\/\/doi.org\/10.1111\/joim.12590","journal-title":"J Intern Med"},{"issue":"1","key":"3546_CR47","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ajh.24236","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV (2016) Myeloma today: disease definitions and treatment advances. Am J Hematol 91(1):90\u2013100. \n                    https:\/\/doi.org\/10.1002\/ajh.24236","journal-title":"Am J Hematol"},{"key":"3546_CR48","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Beksac M, Van der Holt B, Dimopoulos M, Carella AM, Ludwig H, Driessen C, Wester R, Hajek R, Croockewit S, Troia R, Gay F, Cafro AM, De Rosa L, Fioritoni G, Mellqvist UH, Johnsen HE, Zweegman S, Wu KL, Parreira J, Schjesvold FH, D\u2019Rozario J, Palumbo A, Cavo M (2016) Consolidation followed by maintenance therapy versus maintenance alone in newly diagnosed, transplant eligible patients with multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02\/HO95 MM trial). ASH Annual Meeting Abstracts A242","DOI":"10.1182\/blood.V128.22.242.242"},{"key":"3546_CR49","doi-asserted-by":"crossref","unstructured":"Stadtmauer E, Pasquini MC, Blackwell B, Knust K, Bashy A, Devine SM, Efebera YA, Ganguly S, Gasparetto C, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Landau H, McCarthy P, McClune B, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Somlo G, Krishnan A (2016) Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (Len) and dexamethasone (RVD) consolidation with Len maintenance (ACM), tandem autoHCT with Len maintenance (TAM) and autoHCT with Len maintenance (AM) for up-front treatment of patients with multiple myeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702-StaMINA trial). ASH Annual Meeting Abstracts LBA-1","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1"},{"key":"3546_CR50","doi-asserted-by":"publisher","unstructured":"Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Yakoub Agha I, Bourhis JH, Garderet L, Pegourie B, Dumontet C, Renaud M, Voillat L, Berthou C, Marit G, Monconduit M, Caillot D, Grobois B, Avet-Loiseau H, Moreau P, Facon T, Inter-Groupe Francophone du Myelome (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289\u20133294. \n                    https:\/\/doi.org\/10.1182\/blood-2006-05-022962","DOI":"10.1182\/blood-2006-05-022962"},{"key":"3546_CR51","doi-asserted-by":"crossref","unstructured":"Attal M, Palumbo A, Holstein SA, Lauwers-Cances V, Petrucci MT, Richardson PG, Hulin C, Tosi P, Anderson KC, Caillot D, Magarotto V, Moreau P, Marit G, Yu Z, McCarthy PL (2016) Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS). J Clin Oncol 34(suppl; abstr 8001)","DOI":"10.1200\/JCO.2016.34.15_suppl.8001"},{"issue":"3","key":"3546_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.23","volume":"7","author":"S Sengsayadeth","year":"2017","unstructured":"Sengsayadeth S, Malard F, Savani BN, Garderet L, Mohty M (2017) Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J 7(3):e545. \n                    https:\/\/doi.org\/10.1038\/bcj.2017.23","journal-title":"Blood Cancer J"},{"key":"3546_CR53","doi-asserted-by":"publisher","unstructured":"Jackson GH, Davies F, Pawlyn C, Cairns DA, Striha A, Waterhouse A, Jones J, Kishore B, Garg M, Williams C, Karunanithi K, Lindsay J, Jenner M, Cook G, Kaiser M, Drayson M, Owen RG, Russell N, Gregory W, Morgan GJ, NCRI Haemato-Oncology Clinical Studies Group (2017) Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: results of the Myeloma XI study. J Clin Oncol 35(15 suppl):8009. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.8009","DOI":"10.1200\/JCO.2017.35.15_suppl.8009"},{"key":"3546_CR54","unstructured":"Celgene Ltd (2017) Revlimid (lenalidomide) summary of product characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf\n                    \n                  . Accessed March 2018"},{"key":"3546_CR55","doi-asserted-by":"publisher","unstructured":"Pulte ED, Dmytrijuk A, Nie L, Goldberg KB, McKee AE, Farrell AT, Pazdur R (2018) FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma. Oncologist 23(6):734\u2013739 \n                    https:\/\/doi.org\/10.1634\/theoncologist.2017-0440","DOI":"10.1634\/theoncologist.2017-0440"},{"issue":"2","key":"3546_CR56","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","volume":"32","author":"H Goldschmidt","year":"2018","unstructured":"Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk KM, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P (2018) Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia 32(2):383\u2013390. \n                    https:\/\/doi.org\/10.1038\/leu.2017.211","journal-title":"Leukemia"},{"issue":"19","key":"3546_CR57","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","volume":"126","author":"A Larocca","year":"2015","unstructured":"Larocca A, Palumbo A (2015) How I treat fragile myeloma patients. Blood 126(19):2179\u20132185. \n                    https:\/\/doi.org\/10.1182\/blood-2015-05-612960","journal-title":"Blood"},{"issue":"8","key":"3546_CR58","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","volume":"112","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, Benevolo G, Derudas D, Dore F, Cavallo F, Gay F, Falco P, Ciccone G, Musto P, Cavo M, Boccadoro M (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112(8):3107\u20133114. \n                    https:\/\/doi.org\/10.1182\/blood-2008-04-149427","journal-title":"Blood"},{"issue":"10","key":"3546_CR59","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R, Garcia-Larana J, Bengoechea E, Martin A, Mediavilla JD, Palomera L, de Arriba F, Gonzalez Y, Hernandez JM, Sureda A, Bello JL, Bargay J, Penalver FJ, Ribera JM, Martin-Mateos ML, Garcia-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalban MA, Lahuerta JJ, Blade J, Miguel JF (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11(10):934\u2013941. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(10)70187-X","journal-title":"Lancet Oncol"},{"issue":"11","key":"3546_CR60","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","volume":"126","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV (2015) Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood 126(11):1294\u20131301. \n                    https:\/\/doi.org\/10.1182\/blood-2014-12-613927","journal-title":"Blood"},{"issue":"2","key":"3546_CR61","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00277-015-2537-2","volume":"95","author":"VT Hungria","year":"2016","unstructured":"Hungria VT, Crusoe EQ, Maiolino A, Bittencourt R, Fantl D, Maciel JF, Pessoa de Magalhaes RJ, Almeida MS, Cury P, Hisgashi F, Peres AL, Chiattone CS (2016) Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. Ann Hematol 95(2):271\u2013278. \n                    https:\/\/doi.org\/10.1007\/s00277-015-2537-2","journal-title":"Ann Hematol"},{"issue":"9","key":"3546_CR62","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","volume":"127","author":"V Magarotto","year":"2016","unstructured":"Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A (2016) Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 127(9):1102\u20131108. \n                    https:\/\/doi.org\/10.1182\/blood-2015-08-662627","journal-title":"Blood"},{"key":"3546_CR63","doi-asserted-by":"publisher","unstructured":"Hulin C, Belch A, Shustik C, Petrucci MT, Duhrsen U, Lu J, Song K, Rodon P, Pegourie B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T (2016) Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol 34(30):3609\u20133617 \n                    https:\/\/doi.org\/10.1200\/JCO.2016.66.7295","DOI":"10.1200\/JCO.2016.66.7295"},{"issue":"10068","key":"3546_CR64","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389(10068):519\u2013527. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)31594-X","journal-title":"Lancet"},{"key":"3546_CR65","doi-asserted-by":"publisher","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378(6):518\u2013528. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1714678","DOI":"10.1056\/NEJMoa1714678"},{"issue":"4","key":"3546_CR66","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1182\/blood-2015-08-666537","volume":"127","author":"MV Mateos","year":"2016","unstructured":"Mateos MV, Martinez-Lopez J, Hernandez MT, Ocio EM, Rosinol L, Martinez R, Teruel AI, Gutierrez NC, Martin Ramos ML, Oriol A, Bargay J, Bengoechea E, Gonzalez Y, Perez de Oteyza J, Gironella M, Encinas C, Martin J, Cabrera C, Paiva B, Cedena MT, Puig N, Blade J, Lahuerta JJ, San-Miguel J (2016) Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood 127(4):420\u2013425. \n                    https:\/\/doi.org\/10.1182\/blood-2015-08-666537","journal-title":"Blood"},{"key":"3546_CR67","doi-asserted-by":"publisher","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV (2015) Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125(13):2068\u20132074. \n                    https:\/\/doi.org\/10.1182\/blood-2014-12-615187","DOI":"10.1182\/blood-2014-12-615187"},{"issue":"9","key":"3546_CR68","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","volume":"101","author":"M Engelhardt","year":"2016","unstructured":"Engelhardt M, Dold SM, Ihorst G, Zober A, Moller M, Reinhardt H, Hieke S, Schumacher M, Wasch R (2016) Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica 101(9):1110\u20131119. \n                    https:\/\/doi.org\/10.3324\/haematol.2016.148189","journal-title":"Haematologica"},{"issue":"3","key":"3546_CR69","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/cam4.620","volume":"5","author":"L Bonomo","year":"2016","unstructured":"Bonomo L, Lue J, Jagannath S, Chari A (2016) The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. Cancer Med 5(3):500\u2013505. \n                    https:\/\/doi.org\/10.1002\/cam4.620","journal-title":"Cancer Med"},{"issue":"12","key":"3546_CR70","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","volume":"124","author":"MV Mateos","year":"2014","unstructured":"Mateos MV, Oriol A, Martinez-Lopez J, Teruel AI, Lopez de la Guia A, Lopez J, Bengoechea E, Perez M, Martinez R, Palomera L, de Arriba F, Gonzalez Y, Hernandez JM, Granell M, Bello JL, Bargay J, Penalver FJ, Martin-Mateos ML, Paiva B, Montalban MA, Blade J, Lahuerta JJ, San-Miguel JF (2014) GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 124(12):1887\u20131893. \n                    https:\/\/doi.org\/10.1182\/blood-2014-05-573733","journal-title":"Blood"},{"issue":"3","key":"3546_CR71","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","volume":"137","author":"GJ Morgan","year":"2007","unstructured":"Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M, Davies FE (2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 137(3):268\u2013269. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06538.x","journal-title":"Br J Haematol"},{"issue":"4","key":"3546_CR72","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A (2016) Treatment of relapsed and refractory multiple myeloma. Haematologica 101(4):396\u2013406. \n                    https:\/\/doi.org\/10.3324\/haematol.2015.129189","journal-title":"Haematologica"},{"issue":"5","key":"3546_CR73","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/leu.2015.356","volume":"30","author":"J Laubach","year":"2016","unstructured":"Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG (2016) Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30(5):1005\u20131017. \n                    https:\/\/doi.org\/10.1038\/leu.2015.356","journal-title":"Leukemia"},{"key":"3546_CR74","doi-asserted-by":"publisher","unstructured":"Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC, National Cancer Research Institute Haemato-oncology Clinical Studies Group (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF myeloma X relapse [intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol 3(7):e340\u2013e351. \n                    https:\/\/doi.org\/10.1016\/S2352-3026(16)30049-7","DOI":"10.1016\/S2352-3026(16)30049-7"},{"key":"3546_CR75","doi-asserted-by":"publisher","unstructured":"Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC, National Cancer Research Institute Haemato-oncology Clinical Studies Group (2014) High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI myeloma X relapse [intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 15(8):874\u2013885. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(14)70245-1","DOI":"10.1016\/S1470-2045(14)70245-1"},{"issue":"3","key":"3546_CR76","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.bbmt.2014.11.677","volume":"21","author":"KK Singh Abbi","year":"2015","unstructured":"Singh Abbi KK, Zheng J, Devlin SM, Giralt S, Landau H (2015) Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma. Biol Blood Marrow Transplant 21(3):468\u2013472. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.677","journal-title":"Biol Blood Marrow Transplant"},{"key":"3546_CR77","doi-asserted-by":"crossref","unstructured":"Garderet L, Iacobelli S, van Biezen A, Koster L, Dreger P, Johanssen J-E, Leleu X, Potter M, Krejcj M, Peschel C, Radocha J, Ganser A, Metzner B, Paoli N, Sch\u00e4fer-Eckart K, Pohlreich D, Lenain P, Grasso M, Caillot D, Einsele H, Sengeloev H, Meuleman N, Ciceri F, Sch\u00f6nland S, Kr\u00f6ger N (2016) Outcome of third salvage autologous stem cell transplantation in multiple myeloma. ASH Annual Meeting Abstracts A993","DOI":"10.1182\/blood.V128.22.993.993"},{"issue":"1","key":"3546_CR78","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1182\/asheducation-2014.1.262","volume":"2014","author":"JR Mikhael","year":"2014","unstructured":"Mikhael JR (2014) A practical approach to relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program 2014(1):262\u2013267. \n                    https:\/\/doi.org\/10.1182\/asheducation-2014.1.262","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"20","key":"3546_CR79","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"L Garderet","year":"2012","unstructured":"Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G (2012) Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 30(20):2475\u20132482. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.37.4918","journal-title":"J Clin Oncol"},{"key":"3546_CR80","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood.V124.21.303.303","volume":"124","author":"R Baz","year":"2014","unstructured":"Baz R, Martin TG, Alsina M, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Zhao X, Lin H-Y, Jagannath S (2014) Pomalidomide, cyclophosphamide, and dexamethasone is superior to pomalidomide and dexamethasone in relapsed and refractory myeloma: results of a multicenter randomized phase II study. Blood 124:303","journal-title":"Blood"},{"issue":"5","key":"3546_CR81","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","volume":"132","author":"A Glasmacher","year":"2006","unstructured":"Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschluter M (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132(5):584\u2013593. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05914.x","journal-title":"Br J Haematol"},{"key":"3546_CR82","doi-asserted-by":"publisher","unstructured":"Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123\u20132132. \n                    https:\/\/doi.org\/10.1056\/NEJMoa070594","DOI":"10.1056\/NEJMoa070594"},{"key":"3546_CR83","doi-asserted-by":"publisher","unstructured":"Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133\u20132142. \n                    https:\/\/doi.org\/10.1056\/NEJMoa070596","DOI":"10.1056\/NEJMoa070596"},{"key":"3546_CR84","unstructured":"Amgen Ltd (2017) Second phase 3 study shows KYPROLIS\u00ae (carfilzomib) regimen significantly improves overall survival in patients with relapsed multiple myeloma. \n                    https:\/\/www.amgen.com\/media\/news-releases\/2017\/07\/second-phase-3-study-shows-kyprolis-carfilzomib-regimen-significantly-improves-overall-survival-in-patients-with-relapsed-multiple-myeloma\/\n                    \n                  . Accessed 4 October 2017"},{"key":"3546_CR85","unstructured":"Takeda Pharma A\/S (2016) Ninlaro (ixazomib) summary of product characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003844\/WC500217620.pdf\n                    \n                  . Accessed December 2016"},{"key":"3546_CR86","unstructured":"Celgene Ltd (2015) Imnovid (pomalidomide) summary of product characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002682\/WC500147717.pdf\n                    \n                  . Accessed June 2016"},{"key":"3546_CR87","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood.V124.21.304.304","volume":"124","author":"MQ Lacy","year":"2014","unstructured":"Lacy MQ, LaPlant BR, Laumann KM, Kumar S, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Ailawadhi S, Chanan-Khan A, Stewart AK, Reeder CB, Rajkumar SV, Mikhael JR (2014) Pomalidomide, bortezomib and dexamethasone (PVD) for patients with relapsed lenalidomide refractory multiple myeloma (MM). Blood 124:304","journal-title":"Blood"},{"key":"3546_CR88","doi-asserted-by":"crossref","unstructured":"Bringhen S, Magarotto V, Liberati AM, Belotti A, Larocca A, Gilestro M, Bonello F, Gaidano G, Bertazzoni P, Stocchi R, Ribolla R, Di Sano C, Patriarca F, Passera R, De Paoli L, Oliva S, Cafro AM, Sonneveld P, Palumbo A, Boccadoro M (2016) A multicenter, open label phase I\/II study of carfilzomib, pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma (MM) patients. ASH Annual Meeting Abstracts A1145","DOI":"10.1182\/blood.V128.22.1145.1145"},{"key":"3546_CR89","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1182\/blood-2016-07-726729","volume":"128","author":"T Plesner","year":"2016","unstructured":"Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG (2016) Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood 128:1821\u20131828. \n                    https:\/\/doi.org\/10.1182\/blood-2016-07-726729","journal-title":"Blood"},{"issue":"13","key":"3546_CR90","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373(13):1207\u20131219. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1506348","journal-title":"N Engl J Med"},{"issue":"23","key":"3546_CR91","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","volume":"127","author":"A Jakubowiak","year":"2016","unstructured":"Jakubowiak A, Offidani M, Pegourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A (2016) Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM. Blood 127(23):2833\u20132840. \n                    https:\/\/doi.org\/10.1182\/blood-2016-01-694604","journal-title":"Blood"},{"key":"3546_CR92","unstructured":"Janssen Research & Development LLC (2016) Addition of daratumumab to combination of bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02136134?term=NCT02136134&rank=1\n                    \n                  . Accessed June 2016"},{"key":"3546_CR93","unstructured":"Bristol-Myers Squibb (2016) Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat relapsed or refractory multiple myeloma (ELOQUENT-2). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01239797?term=NCT01239797&rank=1\n                    \n                  . Accessed June 2016"},{"key":"3546_CR94","unstructured":"Janssen Research & Development LLC (2016) A study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02076009?term=NCT02076009&rank=1\n                    \n                  . Accessed June 2016"},{"issue":"3","key":"3546_CR95","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/leu.2015.223","volume":"30","author":"S Lonial","year":"2016","unstructured":"Lonial S, Durie B, Palumbo A, San-Miguel J (2016) Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia 30(3):526\u2013535. \n                    https:\/\/doi.org\/10.1038\/leu.2015.223","journal-title":"Leukemia"},{"key":"3546_CR96","unstructured":"Amgen Ltd (2015) Kyprolis (carfilzomib) summary of product characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003790\/WC500197692pdf\n                    \n                   Accessed June 2016"},{"key":"3546_CR97","unstructured":"Janssen-Cillag NV (2016) Velcade (bortezomib) summary of product characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000539\/WC500048471.pdf\n                    \n                  . Accessed June 2016"},{"issue":"11","key":"3546_CR98","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/leu.2010.190","volume":"24","author":"MQ Lacy","year":"2010","unstructured":"Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F (2010) Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24(11):1934\u20131939. \n                    https:\/\/doi.org\/10.1038\/leu.2010.190","journal-title":"Leukemia"},{"issue":"4","key":"3546_CR99","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","volume":"128","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Rollig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P (2016) Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood 128(4):497\u2013503. \n                    https:\/\/doi.org\/10.1182\/blood-2016-02-700872","journal-title":"Blood"},{"issue":"20","key":"3546_CR100","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","volume":"126","author":"JJ Shah","year":"2015","unstructured":"Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG (2015) Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 126(20):2284\u20132290. \n                    https:\/\/doi.org\/10.1182\/blood-2015-05-643320","journal-title":"Blood"},{"issue":"8","key":"3546_CR101","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S (2017) Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood 130(8):974\u2013981. \n                    https:\/\/doi.org\/10.1182\/blood-2017-05-785246","journal-title":"Blood"},{"key":"3546_CR102","doi-asserted-by":"publisher","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 33(26):2863\u20132869. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","DOI":"10.1200\/JCO.2015.61.2267"},{"issue":"24","key":"3546_CR103","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Blade J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127(24):2955\u20132962. \n                    https:\/\/doi.org\/10.1182\/blood-2016-01-631200","journal-title":"Blood"},{"issue":"1","key":"3546_CR104","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/asheducation-2016.1.485","volume":"2016","author":"A Dispenzieri","year":"2016","unstructured":"Dispenzieri A (2016) Myeloma: management of the newly diagnosed high-risk patient. Hematology Am Soc Hematol Educ Program 2016(1):485\u2013494. \n                    https:\/\/doi.org\/10.1182\/asheducation-2016.1.485","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3546_CR105","doi-asserted-by":"publisher","unstructured":"Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Studies Group (2012) Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC myeloma IX randomized trial results. Haematologica 97(3):442\u2013450. \n                    https:\/\/doi.org\/10.3324\/haematol.2011.043372","DOI":"10.3324\/haematol.2011.043372"},{"issue":"13","key":"3546_CR106","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1182\/blood-2015-06-653261","volume":"126","author":"S Lonial","year":"2015","unstructured":"Lonial S, Boise LH, Kaufman J (2015) How I treat high-risk myeloma. Blood 126(13):1536\u20131543. \n                    https:\/\/doi.org\/10.1182\/blood-2015-06-653261","journal-title":"Blood"},{"key":"3546_CR107","unstructured":"Offidani M, Corvatta L, Bringhen S, Gentili S, Troia R, Maracci L, Larocca A, Palumbo A, Leoni P (2016) Impact of cytogenetic risk on PFS2 of patients treated with different therapy sequences: results of a post-hoc analysis"},{"issue":"10","key":"3546_CR108","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3324\/haematol.2014.117077","volume":"100","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF (2015) Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica 100(10):1327\u20131333. \n                    https:\/\/doi.org\/10.3324\/haematol.2014.117077","journal-title":"Haematologica"},{"key":"3546_CR109","doi-asserted-by":"publisher","unstructured":"Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T, Intergroupe Francophone du Myelome (2015) Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010-02 trial results. Blood 125(9):1411\u20131417. \n                    https:\/\/doi.org\/10.1182\/blood-2014-11-612069","DOI":"10.1182\/blood-2014-11-612069"},{"issue":"9","key":"3546_CR110","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","volume":"128","author":"H Avet-Loiseau","year":"2016","unstructured":"Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P (2016) Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 128(9):1174\u20131180. \n                    https:\/\/doi.org\/10.1182\/blood-2016-03-707596","journal-title":"Blood"},{"key":"3546_CR111","doi-asserted-by":"crossref","unstructured":"Mateos M, Estell J, Barreto W, Corradini P, Min C-K, Medvedova E, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Casneuf T, Chiu C, Sasser AK, Nooka AK (2016) Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of CASTOR. Blood 128(22):92\u20135969 (Abstract 1150)","DOI":"10.1182\/blood.V128.22.1150.1150"},{"key":"3546_CR112","doi-asserted-by":"crossref","unstructured":"Usmani S, Dimopoulos M, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Khokhar N, Guckert M, Wu K, Qin X, Casneuf T, Chiu C, Sasser AK, San Miguel J (2016) Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of POLLUX. Blood 128(22):92\u20135969 (Abstract 1151)","DOI":"10.1182\/blood.V128.22.1151.1151"},{"issue":"22","key":"3546_CR113","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood.V128.22.2417.2417","volume":"128","author":"R H\u00e1jek","year":"2016","unstructured":"H\u00e1jek R, Jarkovsky J, Bouwmeester W, Treur M, DeCosta L, Campioni M, Delforge M, Raab MS, Schoen P, Szabo Z, Lucie B, Gonzalez-McQuire S (2016) Exploration of survival stratification of patients with multiple myeloma after first relapse using real world data. Blood 128(22):2417","journal-title":"Blood"},{"issue":"29","key":"3546_CR114","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","volume":"26","author":"O Decaux","year":"2008","unstructured":"Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 26(29):4798\u20134805. \n                    https:\/\/doi.org\/10.1200\/jco.2007.13.8545","journal-title":"J Clin Oncol"},{"issue":"11","key":"3546_CR115","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P (2012) A gene expression signature for high-risk multiple myeloma. Leukemia 26(11):2406\u20132413. \n                    https:\/\/doi.org\/10.1038\/leu.2012.127","journal-title":"Leukemia"},{"issue":"6","key":"3546_CR116","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr","year":"2007","unstructured":"Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109(6):2276\u20132284. \n                    https:\/\/doi.org\/10.1182\/blood-2006-07-038430","journal-title":"Blood"},{"issue":"5","key":"3546_CR117","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","volume":"123","author":"G Mulligan","year":"2014","unstructured":"Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M (2014) Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 123(5):632\u2013639. \n                    https:\/\/doi.org\/10.1182\/blood-2013-05-504340","journal-title":"Blood"},{"issue":"33","key":"3546_CR118","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ (2015) Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 33(33):3911\u20133920. \n                    https:\/\/doi.org\/10.1200\/jco.2014.59.1503","journal-title":"J Clin Oncol"},{"issue":"22","key":"3546_CR119","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C (2017) Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 130(22):2401\u20132409. \n                    https:\/\/doi.org\/10.1182\/blood-2017-06-788786","journal-title":"Blood"},{"issue":"19","key":"3546_CR120","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119(19):4375\u20134382. \n                    https:\/\/doi.org\/10.1182\/blood-2011-11-395749","journal-title":"Blood"},{"key":"3546_CR121","unstructured":"Intergroupe Francophone du Myelome (2016) A study to evaluate daratumumab in transplant eligible participants with previously untreated multiple myeloma (Cassiopeia). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02541383?term=NCT02541383&rank=1\n                    \n                  . Accessed June 2016"},{"key":"3546_CR122","unstructured":"Bristol-Myers Squibb (2016) Study of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in multiple myeloma (CheckMate 602). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02726581?term=NCT02726581&rank=1\n                    \n                  . Accessed June 2016"},{"key":"3546_CR123","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.critrevonc.2017.02.007","volume":"112","author":"P Sonneveld","year":"2017","unstructured":"Sonneveld P, De Wit E, Moreau P (2017) How have evolutions in strategies for the treatment of relapsed\/refractory multiple myeloma translated into improved outcomes for patients? Crit Rev Oncol Hematol 112:153\u2013170. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"3546_CR124","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/jcpt.12020","volume":"38","author":"JG Gaultney","year":"2013","unstructured":"Gaultney JG, Franken MG, Tan SS, Redekop WK, Huijgens PC, Sonneveld P, Uyl-de Groot CA (2013) Real-world health care costs of relapsed\/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther 38(1):41\u201347. \n                    https:\/\/doi.org\/10.1111\/jcpt.12020","journal-title":"J Clin Pharm Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3546-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3546-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3546-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T19:11:20Z","timestamp":1574449880000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3546-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3546"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3546-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"23 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HG has received research support from Bristol-Myers Squibb, Celgene Ltd., Chugai, Janssen, Millenium Pharmaceuticals, Inc., and Novartis International AG, has participated in advisory boards for Amgen, Bristol-Myers Squibb, Celgene Ltd., Janssen, Novartis International AG, Onyx Pharmaceuticals, Inc., and Takeda, and has received honoraria from Celgene Ltd., Chugai, Janssen, Millenium Pharmaceuticals, Inc., Novartis International AG, and Onyx Pharmaceuticals, Inc. JA has participated in advisory boards and as a consultant for Amgen, Celgene Ltd., Janssen, and Takeda. ZS is an employee of Amgen and holds stock. LG is a consultant for Amgen, Novartis International AG, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}